

**Aus dem Max Planck Institut für molekulare Genetik
Research Group Development & Disease**

**Investigating the Molecular Mechanisms Underlying
Geroderma Osteodysplastica (GO) Syndrome**

**Dissertation zur Erlangung des akademischen Grades
Doktor der Naturwissenschaften
(Dr. rer. nat.)**

**Eingereicht im
Fachbereich Biologie, Chemie, Pharmazie
der Freien Universität Berlin**

vorgelegt von

Haikuo Zhang

aus Shandong, China

April 2008

1. Gutachter: Prof. Dr. Stefan Mundlos

Max-Planck-Institut für Molekulare Genetik

Inhnestr. 73, 14195 Berlin

Tel: 030-84131267

Email: mundlos@molgen.mpg.de

2. Gutachter: Prof. Dr. Ansgar Klebes

Freie Universität Berlin

Institut für Biologie – Genetik,

Arnimallee 7, 14195 Berlin

Tel. 030-83855138

Email: klebes@genetik.fu-berlin.de

Disputation am: 02.07.2008

Acknowledgements

First of all, I would like to express my highest gratitude to my supervisor Prof. Dr. Stefan Mundlos for providing me with the opportunity to carry out this Ph.D program followed by his thoughtful guidance and kind support throughout the study. His attitude toward science and style of working is highly cherished: faithfulness, preciseness, and persistence, which would definitely influence me even in my future scientific career.

Particular thanks go to Dr. Uwe Kornak, my project leader and work partner. As an excellent scientist, he led me into the basis of GO project. With his kind help and support, I have been fortunate to get into GO project so quickly. I have been keeping close communication with him during the last two years and I really benefit from the insightful discussion with him.

I am grateful to the collaborators, whose elegant work reinforced this project substantially: Group of Dr. Francis A. Barr (MPI for Biochemistry, Martinsried) for Y2H screening and Dr. Willy Morelle (CNRS/USTL, France) for Maldi-Tof-MS analysis.

I would also express my gratitude to Dr. Heinrich Schrewe (Dept. Developmental Genetics) for helping diagnose the lung phenotype of our mutant mice and providing antibodies against surfactant proteins, to Dr. Rudi Lurz for showing me the exquisite skills to use laser scanning microscope Zeiss LSM510, and to Prof. Dr. Juan S. Bonifacino (NIH, USA) for providing Arf1-T31N construct as a kind gift.

I really appreciate the helpful communication with Prof. Dr. George M. Martin (University of Washington). His encouraging comments on the discussion section add much luster to this manuscript.

I would express my gratitude to Prof. Dr. Ansgar Klebes for being my advisor at FU and reviewing this thesis, to Dr. Uwe Kornak and Dr. Peter N. Robinson (Charité CVK) for correcting the manuscript.

I am greatly indebted to Dr. Santosh Nigam (Charité CBF) for initially inviting me to Berlin. I can safely say that Berlin, a fascinating city, is a dreamland for one with a will.

I would thank my colleagues at Research Group Development & Disease, MPI for Molecular Genetics and colleagues at Institute for Medical Genetics, Charité CVK for their support and concern during the last 3.5 years. Especially, I benefited from the help kindly offered by Ulrich Wilkening and Dr. Nicole Verhey van Wijk. I enjoyed some agreeable time together with Dr. Sigmar Stricker, Dr. Petra Seemann, Dr. Andrea Albrecht, Dr. Mateusz Kolanczyk, Dr. Pablo Villavicencio-Lorini, Dr. Barbara Dlugaszewska, Norbert Brieske, Christine Zwingmann and so on. I would also thank Dr. Lei Mao (Charité CVK) for the technical help with Mass Spectrometry.

I would like to mention Prof. Dr. Zeguang Han (CHGC, Shanghai), a reliable friend as well as a kind teacher, for his kind help over the last years.

Finally, I would give my special thanks to my family: my parents and sisters in China, my wife and my child in Berlin. Their understanding and lasting support enable me to get this far. Together with my wife Xin and my daughter Yufei in Berlin, I have been feeling the life full of joy and happiness. Additionally, as a guest scientist, Xin made quite some contribution to this project.

This thesis is dedicated to my wife and my child.

Table of contents

1. INTRODUCTION.....	7
1.1 Skin and premature ageing disorders.....	8
1.1.1 Skin.....	8
1.1.2 Skin ageing	9
1.1.3 Cutis laxa.....	9
1.1.3.1 Elastin.....	9
1.1.3.2 Fibulins.....	10
1.2 Bone and osteoporosis.....	11
1.2.1 Bone development.....	12
1.2.1.1 Skeletal patterning.....	12
1.2.1.2 Chondrocyte differentiation.....	12
1.2.1.3 Osteoblast differentiation.....	13
1.2.1.4 Osteoclast formation.....	13
1.2.1.5 Extracellular matrix.....	14
1.2.2 Osteoporosis.....	14
1.3 Geroderma osteodysplastica (GO) and its genetic basis.....	15
1.3.1 History of GO.....	15
1.3.2 Molecular basis of GO.....	17
2. MATERIALS AND METHODS.....	19
2.1 Materials.....	19
2.1.1 Chemicals and reagents.....	19
2.1.2 Buffers and solutions.....	21
2.1.3 Antibodies and kits.....	24
2.1.4 Primers.....	25
2.2 Methods.....	29
2.2.1 RNA isolation.....	29
2.2.2 RT-PCR analysis.....	29
2.2.3 Cell culture and DNA transfection.....	29
2.2.4 Immunofluorescence analysis.....	29
2.2.5 Chicken bone marrow system.....	29
2.2.6 Expression analysis in mouse embryos.....	30
2.2.7 Yeast two-hybrid analysis and GST pull-down.....	30
2.2.8 RNA interference.....	31
2.2.9 SDS-PAGE and Western blot analysis.....	31
2.2.10 Synthesis of RNA probes for <i>in situ</i> hybridization.....	31
2.2.11 Whole mount <i>in situ</i> hybridization.....	32
2.2.12 Section <i>in situ</i> hybridization.....	33

2.2.13 Quantitative PCR.....	34
2.2.14 Immunohistochemistry.....	34
2.2.15 Lectin blot and lectin histochemistry.....	34
2.2.16 Mass spectrometric analysis of N- and O-linked glycans.....	35
2.2.17 Databases and bioinformatic analysis.....	35
3. RESULTS.....	36
3.1 SCYL1BP1 is a new member of Golgi-resident proteins.....	36
3.1.1 Preparing polyclonal and monoclonal antibodies.....	36
3.1.2 Verifying polyclonal and monoclonal antibodies.....	36
3.1.3 Subcellular localization.....	39
3.1.4 Western blot in primary human fibroblasts.....	41
3.1.5 Co-localization of SCYL1BP1 with Golgi markers.....	41
3.1.6 Response of SCYL1BP1 to Brefeldin A and Nocodazole.....	42
3.1.7 Response of SCYL1BP1 to mutant form of Arf1.....	44
3.2 Generation and characterization of gene-trap mice.....	46
3.2.1 Gene trap ES cell line.....	46
3.2.2 Generation of gene trap mouse.....	46
3.2.3 Mapping the insertion site.....	48
3.2.4 Genotyping.....	48
3.2.5 Analysis of Scyl1bp1 expression.....	48
3.3 Phenotype of Scyl1bp1 deficient mice.....	50
3.3.1 Lethality phenotype.....	50
3.3.1.1 Lethality of homozygotes.....	50
3.3.1.2 Identifying homozygotes at embryonic stages.....	50
3.3.1.3 Respiratory insufficiency in newborn homozygotes.....	52
3.3.1.4 Surfactant proteins in the mutant lungs.....	52
3.3.2 Skin phenotype.....	53
3.3.3 Bone phenotype.....	54
3.4 Scyl1bp1 is ubiquitously expressed with higher level in lung, skin, cartilage and osteoblasts...	55
3.4.1 <i>in situ</i> hybridization and RealTime PCR.....	55
3.4.2 X-gal staining.....	57
3.4.3 Immunostaining.....	59
3.5 SCYL1BP1 specifically interacts with Rab6.....	59
3.5.1 Y2H screen.....	59
3.5.1.1 Y2H constructs.....	60
3.5.1.2 Binding partners.....	63
3.5.1.3 SiRNA against Scyl1bp1.....	63
3.5.2 Secretion of proteins involved in elastogenesis.....	64
3.6 Glycosylation defect.....	67

3.7 Chip data analysis.....	71
4. DISCUSSION.....	74
4.1 GO is caused by loss-of-function of the golgin protein SCYL1BP1.....	74
4.2 How does SCYL1BP1 function as a golgin?.....	76
4.3 Membrane trafficking and GO.....	78
4.4 lung development and respiratory distress.....	80
4.5 Glycosylation defect.....	82
4.6 GO provides a distinct mechanism for progeroid syndromes.....	83
4.7 Emerging roles of Golgi in ageing.....	84
5. SUMMARY.....	86
6. ZUSAMMENFASSUNG.....	87
7. REFERENCES.....	88
APPENDIX.....	100